UTR6 Antibody
Description
Clarification of Terminology
The term "UTR6" may involve a potential misunderstanding:
-
UTR typically refers to "untranslated regions" in mRNA (5'UTR or 3'UTR), which regulate gene expression but are not direct antibody targets.
-
IL-6 (Interleukin-6) is a well-characterized cytokine with antibodies like tocilizumab and clazakizumab targeting its receptor (IL-6R) .
-
No antibodies designated as "UTR6" are documented in immunology or biotechnology contexts.
Relevant Antibodies Targeting IL-6/IL-6R
While "UTR6 Antibody" remains unidentified, several anti-IL-6/IL-6R antibodies are clinically significant:
Tocilizumab
-
Target: IL-6 receptor (IL-6R)
-
Applications: Rheumatoid arthritis, cytokine release syndrome
-
Efficacy: Achieved ACR20/50/70 responses in 61%/38%/21% of RA patients, respectively .
Clazakizumab
-
Target: IL-6
-
Applications: Late antibody-mediated rejection in kidney transplants
-
Results: Reduced donor-specific antibodies (DSAs) and slowed eGFR decline (-0.96 vs. -2.43 mL/min/1.73 m²/month for placebo) .
| Antibody | Target | Indication | Key Efficacy Metric |
|---|---|---|---|
| Tocilizumab | IL-6R | Rheumatoid arthritis | ACR20: 61%, DAS remission: 30% |
| Clazakizumab | IL-6 | Transplant rejection | eGFR decline: -0.96 mL/min/1.73 m² |
Methodological Insights from Antibody Studies
Key techniques for antibody validation include:
-
DSA Monitoring: Serial dilution assays to quantify antibody levels .
-
Molecular Profiling: Biopsy-based gene-expression analysis to assess rejection activity .
-
Safety Metrics: Tracking infections (25% rate with clazakizumab) and diverticular complications .
Recommendations for Further Inquiry
If "UTR6 Antibody" refers to a novel or proprietary compound:
-
Verify nomenclature with the original source.
-
Consult patent databases (e.g., USPTO, WIPO) for unpublished candidates.
-
Explore preclinical studies in niche journals or conference abstracts.
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
